Jennison Associates’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Jennison Associates’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-86,670	Closed	-$14.7M	–	633
2023 Q3	$14.7M	Buy	86,670 +40,880	+89%	+$7.69M	0.01%	340
2023 Q2	$9.93M	Buy	+45,790	New	+$9.81M	0.01%	380
2022 Q2	–	Sell	-273,540	Closed	-$34.7M	–	715
2022 Q1	$34.7M	Buy	273,540 +93,290	+52%	+$10.5M	0.03%	279
2021 Q4	$23.6M	Buy	180,250 +91,909	+104%	+$11.9M	0.02%	336
2021 Q3	$10.8M	Buy	+88,341	New	+$10.2M	0.01%	443

Other funds holding KRTX

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jennison Associates's KRTX Position: Q4 2023 in Review

Jennison Associates sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 86,670 shares — an estimated $14.7M sold.

Jennison Associates first reported a position in KRTX in Q3 2021 and held it in 5 quarters. The position peaked at $34.7M in Q1 2022. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

Jennison Associates reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Jennison Associates sold 86,670 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $14.7M.
Jennison Associates first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Jennison Associates's Karuna Therapeutics, Inc. Common Stock position peaked at $34.7M in Q1 2022.
328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Jennison Associates's 13F filing for Q4 2023, filed 1 Feb 2024.